INO INOVIO PHARMACEUTICALS, INC.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1055726 · Fiscal year ends 12/31
Financial factors as of 2025-12-31 (2025Q4), TTM = sum of the last four quarters
Growth
TTM revenue YoY-70.0%
TTM net income YoY20.8%
TTM EPS YoY54.2%
Revenue 3-yr CAGR-81.5%
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-132,871.3%
Net margin-130,000.0%
FCF margin-136,074.5%
EBITDA margin-130,701.4%
Returns
ROE-183.5%
ROA-90.6%
ROIC (approx.)—
Asset turnover0.00x
Leverage & solvency
Liabilities / assets67.6%
Debt / equity0.00x
Current ratio1.40x
Interest coverage—
Cash quality & payout
Operating cash flow / net income1.04x
Accruals ratio3.9%
Payout ratio—
Capex / revenue437.2%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $298,901 | $0 | $0 | $0 | $0 | $0 | $65,343 | $116,994 |
| R&D expense | $10.62M | $10.83M | $14.07M | $10.26M | $13.33M | $14.52M | $16.09M | $12.89M |
| SG&A expense | $9.21M | $7.80M | $7.88M | $7.22M | $7.88M | $8.56M | $9.02M | $7.60M |
| Operating income | -$19.52M | -$18.62M | -$21.95M | -$17.48M | -$21.21M | -$23.08M | -$25.05M | -$20.37M |
| Interest expense | — | — | — | $0 | $0 | $0 | $0 | $0 |
| Net income | -$49.20M | -$6.01M | -$19.68M | $3.76M | -$45.50M | -$23.52M | -$19.69M | -$19.38M |
| EBITDA | -$19.20M | -$18.30M | -$21.63M | -$17.14M | -$20.86M | -$22.73M | -$24.68M | -$19.95M |
| EPS (basic) | -0.50 | -0.07 | -0.28 | — | -0.87 | -0.61 | -0.51 | — |
| EPS (diluted) | -0.50 | -0.07 | -0.28 | — | -0.87 | -0.61 | -0.51 | — |
| Weighted avg. shares (diluted) | 98.63M | 81.62M | 69.10M | — | 52.17M | 38.83M | 38.61M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $46.96M | $31.53M | $26.27M | $44.27M | $36.57M | $24.35M | $39.92M | $65.81M |
| Short-term investments | $1.40M | $5.15M | $11.41M | $14.24M | $14.24M | $23.20M | $28.45M | $28.30M |
| Receivables | — | — | — | $450 | $978,590 | $840,312 | $1.31M | $1.20M |
| Current assets | $51.44M | $39.91M | $39.44M | $61.12M | $55.18M | $52.70M | $71.89M | $97.83M |
| PP&E, net | $1.57M | $1.89M | $2.21M | $2.53M | $2.74M | $3.09M | $3.35M | $3.66M |
| Total assets | $60.14M | $49.39M | $49.78M | $74.31M | $69.39M | $68.24M | $87.27M | $113.20M |
| Current liabilities | $89.47M | $39.92M | $37.92M | $43.67M | $69.82M | $31.71M | $27.33M | $35.33M |
| Total liabilities | $94.06M | $45.02M | $43.71M | $50.21M | $77.11M | $39.71M | $36.02M | $44.69M |
| Shareholders' equity | -$33.92M | $4.37M | $6.07M | $24.10M | -$7.72M | $28.53M | $51.25M | $68.50M |
| Shares outstanding | 110.18M | 82.34M | 69.77M | 69.00M | 53.57M | 36.72M | 36.67M | 36.10M |
| Cash flow statement | ||||||||
| Operating cash flow | -$15.27M | -$18.05M | -$21.59M | -$19.37M | -$21.57M | -$20.81M | -$26.87M | -$19.66M |
| Capital expenditure | $0 | $0 | $0 | $127,444 | $67,951 | $30,930 | $59,373 | $0 |
| Free cash flow | -$15.27M | -$18.05M | -$21.59M | -$19.50M | -$21.64M | -$20.84M | -$26.93M | -$19.66M |
| Investing cash flow | $3.72M | $6.15M | $2.64M | -$58,189 | $8.87M | $5.28M | -$51,753 | $34.64M |
| Financing cash flow | $26.99M | $17.16M | $953,790 | $27.13M | $24.92M | -$34,777 | $1.03M | $29.15M |
| Depreciation & amortization | $322,034 | $322,034 | $316,844 | $340,197 | $350,198 | $356,151 | $371,367 | $416,821 |
| Stock-based compensation | $868,002 | $768,437 | $698,744 | $764,561 | $757,086 | $834,792 | $1.40M | $1.32M |
Free plan shows the latest 8 periods; Pro shows all 66 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.